Kevin Sin has joined GlaxoSmithKline as its senior vice president, head of worldwide business development for pharmaceutical research and development.
In this position, Sin will play a role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of new medicines for patients.
He said: “The incredible pace of scientific and technical innovation that is happening around the world is significant and presents an abundance of opportunities to combine GSK’s strengths and capabilities with that of others to pursue big ideas in science and medicine.
“I look forward to working with the team to explore collaborations that can accelerate the discovery and development of new medicines with the potential to significantly improve human health.”
Sin joins GSK from Genetech, where he served as vice president and global head of oncology business development and has worked within the pharmaceutical and life science industry for over 20 years.
Dr Hal Barron, chief scientific officer and president of research and development, GSK, said: “I am extremely excited to have Kevin join GSK. Gaining access to the best science and technologies across the world as well as establishing highly productive collaborations with academia and industry, play an important role in creating a world-class R&D organization.
“Kevin’s leadership skills, significant expertise and successful track record make him the ideal person to lead Business Development activities for R&D.”
Sin will report to Hal Barron and will be based at the group’s San Francisco office.